GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Cyclically Adjusted Book per Share

CANF (Can Fite Biofarma) Cyclically Adjusted Book per Share : $41.91 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Can Fite Biofarma's adjusted book value per share for the three months ended in Dec. 2024 was $0.547. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $41.91 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Can Fite Biofarma's average Cyclically Adjusted Book Growth Rate was -9.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Can Fite Biofarma was -2.90% per year. The lowest was -4.90% per year. And the median was -3.90% per year.

As of today (2025-05-15), Can Fite Biofarma's current stock price is $1.045. Can Fite Biofarma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $41.91. Can Fite Biofarma's Cyclically Adjusted PB Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Can Fite Biofarma was 0.52. The lowest was 0.03. And the median was 0.16.


Can Fite Biofarma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Can Fite Biofarma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Cyclically Adjusted Book per Share Chart

Can Fite Biofarma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.77 50.02 42.33 45.69 41.91

Can Fite Biofarma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.87 45.77 45.69 38.70 41.91

Competitive Comparison of Can Fite Biofarma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Can Fite Biofarma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Cyclically Adjusted PB Ratio falls into.


;
;

Can Fite Biofarma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Can Fite Biofarma's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.547/133.1571*133.1571
=0.547

Current CPI (Dec. 2024) = 133.1571.

Can Fite Biofarma Quarterly Data

Book Value per Share CPI Adj_Book
201409 42.695 100.428 56.609
201412 91.296 99.070 122.709
201503 84.394 99.621 112.804
201506 64.219 100.684 84.931
201509 96.690 100.392 128.248
201512 112.130 99.792 149.620
201603 100.000 100.470 132.534
201606 82.160 101.688 107.586
201609 63.576 101.861 83.109
201612 42.011 101.863 54.918
201703 53.248 102.862 68.931
201706 36.189 103.349 46.627
201709 31.798 104.136 40.660
201712 45.171 104.011 57.829
201803 55.857 105.290 70.641
201806 48.947 106.317 61.304
201809 47.311 106.507 59.149
201812 22.333 105.998 28.055
201903 21.633 107.251 26.858
201906 25.425 108.070 31.327
201909 17.684 108.329 21.737
201912 6.075 108.420 7.461
202003 0.000 108.902 0.000
202006 6.678 108.767 8.175
202009 6.191 109.815 7.507
202012 3.929 109.897 4.761
202103 4.118 111.754 4.907
202106 2.301 114.631 2.673
202109 4.651 115.734 5.351
202112 5.289 117.630 5.987
202203 4.422 121.301 4.854
202206 3.638 125.017 3.875
202209 2.732 125.227 2.905
202212 1.645 125.222 1.749
202303 2.080 127.348 2.175
202306 1.684 128.729 1.742
202309 1.282 129.860 1.315
202312 1.377 129.419 1.417
202406 0.445 132.554 0.447
202412 0.547 133.157 0.547

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Can Fite Biofarma  (AMEX:CANF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Can Fite Biofarma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.045/41.91
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Can Fite Biofarma was 0.52. The lowest was 0.03. And the median was 0.16.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Can Fite Biofarma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma Business Description

Industry
Traded in Other Exchanges
Address
26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma Headlines